Merck & Co., Inc. $MRK Shares Acquired by First American Bank

Key Points

• First American Bank increased its stake in Merck & Co., Inc. by 23.0%, owning 75,841 shares worth $6,004,000 by the end of the last quarter.
• Several institutional investors significantly boosted their holdings in Merck during the first quarter, with Charles Schwab increasing its stake by 144.6% and Pacer Advisors by 2,240.9%.
• The company recently declared a quarterly dividend of $0.81 per share, with a dividend yield of 4.1%, highlighting its continued commitment to returning value to shareholders.

First American Bank lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 75,841 shares of the company's stock after purchasing an additional 14,159 shares during the quarter. First American Bank's holdings in Merck & Co., Inc. were worth $6,004,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in MRK. Charles Schwab Investment Management Inc. grew its stake in shares of Merck & Co., Inc. by 144.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company's stock worth $4,418,820,000 after purchasing an additional 29,104,112 shares during the period. Nuveen LLC acquired a new position in shares of Merck & Co., Inc. during the 1st quarter worth $991,553,000. Pacer Advisors Inc. grew its stake in shares of Merck & Co., Inc. by 2,240.9% during the 1st quarter. Pacer Advisors Inc. now owns 5,286,801 shares of the company's stock worth $474,543,000 after purchasing an additional 5,060,959 shares during the period. GAMMA Investing LLC grew its stake in shares of Merck & Co., Inc. by 9,991.9% during the 1st quarter. GAMMA Investing LLC now owns 4,332,446 shares of the company's stock worth $388,880,000 after purchasing an additional 4,289,516 shares during the period. Finally, Amundi grew its stake in shares of Merck & Co., Inc. by 37.1% during the 1st quarter. Amundi now owns 13,077,716 shares of the company's stock worth $1,130,397,000 after purchasing an additional 3,542,036 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Morgan Stanley lowered their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Wells Fargo & Company lowered their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 30th. Finally, Berenberg Bank cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $106.41.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $78.51 on Friday. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $114.79. The stock has a market cap of $196.10 billion, a price-to-earnings ratio of 12.10, a PEG ratio of 0.80 and a beta of 0.37. The company's 50-day moving average price is $82.53 and its 200 day moving average price is $81.98. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company had revenue of $15.81 billion for the quarter, compared to analysts' expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a dividend yield of 4.1%. The ex-dividend date of this dividend is Monday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 49.92%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.